Natixis Advisors Boosts Bristol Myers Squibb Stake

Asset manager increases holdings in pharmaceutical company by 8.2% in Q3

Mar. 11, 2026 at 9:54am

Got story updates? Submit your updates here. ›

Natixis Advisors LLC, an investment management firm, increased its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 8.2% in the third quarter, according to a recent filing with the Securities and Exchange Commission. The fund now owns 590,260 shares of the biopharmaceutical company's stock, valued at $26.6 million as of the end of the quarter.

Why it matters

Bristol Myers Squibb is a major pharmaceutical company focused on developing treatments for cancer, immune-mediated diseases, and other serious conditions. The increase in Natixis Advisors' stake suggests the asset manager sees continued growth potential in the company's pipeline and commercial products.

The details

According to the SEC filing, Natixis Advisors added 44,698 shares of Bristol Myers Squibb to its portfolio during the third quarter. The asset manager now holds a total of 590,260 shares, making it one of the company's institutional investors. Bristol Myers Squibb's stock has seen strong performance in recent quarters, driven by the success of key drugs like Opdivo and Eliquis.

  • Natixis Advisors increased its Bristol Myers Squibb stake in the third quarter of 2026.

The players

Natixis Advisors LLC

An investment management firm that oversees over $590 billion in assets.

Bristol Myers Squibb Company

A global biopharmaceutical company focused on developing innovative medicines for serious diseases.

Got photos? Submit your photos here. ›

The takeaway

The increased stake from Natixis Advisors suggests continued confidence in Bristol Myers Squibb's ability to deliver growth and shareholder value through its diverse portfolio of pharmaceutical products and robust R&D pipeline.